Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol.
Hosogaya N, Takazono T, Ota K, Kiya R, Shirai Y, Kawasaki R, Yano H, Morimoto S, Nakao R, Kanamaru Y, Yoshino Y, Ishikawa Y, Fukushima C, Yamamoto H, Izumikawa K, Yanagihara K, Mukae H. Hosogaya N, et al. Among authors: fukushima c. Medicine (Baltimore). 2023 Feb 22;102(8):e33092. doi: 10.1097/MD.0000000000033092. Medicine (Baltimore). 2023. PMID: 36827005 Free article.
Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T, Sato S, Miyamoto J, Hagimori N, Kawazoe Y, Arinaga K, Fukushima C, Yamamoto H, Kawakami A. Koga T, et al. Among authors: fukushima c. Trials. 2018 Dec 29;19(1):715. doi: 10.1186/s13063-018-3105-6. Trials. 2018. PMID: 30594222 Free PMC article.
An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial.
Koga T, Hagimori N, Sato S, Morimoto S, Hosogaya N, Fukushima C, Yamamoto H, Kawakami A. Koga T, et al. Among authors: fukushima c. Medicine (Baltimore). 2020 Jan;99(1):e18328. doi: 10.1097/MD.0000000000018328. Medicine (Baltimore). 2020. PMID: 31895769 Free PMC article.
Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial.
Koga T, Hagimori N, Takemori S, Morimoto S, Sumiyoshi R, Shimizu T, Hosogaya N, Fukushima C, Yamamoto H, Kawakami A. Koga T, et al. Among authors: fukushima c. Medicine (Baltimore). 2020 Jul 24;99(30):e20710. doi: 10.1097/MD.0000000000020710. Medicine (Baltimore). 2020. PMID: 32791665 Free PMC article.
Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
Kawashiri SY, Shimizu T, Sato S, Morimoto S, Kawazoe Y, Sumiyoshi R, Hosogaya N, Fukushima C, Yamamoto H, Kawakami A. Kawashiri SY, et al. Among authors: fukushima c. Medicine (Baltimore). 2020 Jul 24;99(30):e21151. doi: 10.1097/MD.0000000000021151. Medicine (Baltimore). 2020. PMID: 32791688 Free PMC article.
150 results